Revvity, Inc. (RVTY) Stock: Price, Forecast & Analyst Target
Revvity, Inc. (RVTY) — MoonshotScore 72/100 (Strong band), calculated Oct 26, 2026. Price $160.39 (+1.02%), as of the Oct 26, 2026 trading session; market cap $17.9B. Expected results Nov 3, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 17.50× (market value Oct 26, 2026; cash Jul 5, 2026) · expected results Nov 3, 2026
Revvity, Inc. · RVTY · NYSE · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-13: Revvity supplies the instruments, reagents, assays, software and laboratory services used in life-science research and diagnostic screening; it is not primarily a testing laboratory. The case rests on whether recovering demand and a broad consumables-and-tools portfolio can lift reported profit while reinvestment, a pending divestiture and a sizable net debt position remain in view.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore v2 · Revvity (RVTY)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but weak growth; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Full; Growth Durability: Fading; Momentum: Surging.
- quarterly revenue $730M (Q2 FY2026, quarter ended Jul 5, 2026)
- EPS beat 8 of 8
- Altman Z 3.36 · Piotroski F 8
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 72 | Strong | |
| 72 | Strong | |
| 72 | Strong | |
| 72 | Strong | |
| 71 | Strong | |
| 72 | Strong |
The score was 72 in the stored Oct 24, 2026 snapshot and remains 72 in the current publication computed Oct 26, 2026 (0); the largest pillar moves were Financial Safety +1 and Growth Durability +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $160.39 | |
| Change on the day | +1.02% | |
| 52-week range | $81.22–$166.25 | |
| Market capitalisation | $17.9B | |
| Price / earnings (trailing) | 75.60 | |
| Shares traded on the day | 1.09M | |
| Beta (volatility vs the S&P 500) | 1.06 | |
| Dividends per share (last 12 months) | $0.28 | |
| Dividend yield (last 12 months) | 0.18% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We expect to be able to generate adjusted operating margins of approximately 28.7% this year due to the stronger organic growth we now expect for the year, combined with the impact of the tariff refunds we've received, which is being partially offset by incremental reinvestments we are making in our strategic initiatives, supply chain and in our people, which should allow us to capitalize on the end market recovery that we believe is now underway.
Prahlad Singh · Statement from
As a reminder, given the pending divestiture of our immunodiagnostics business in China, all of the following commentary and our updated guidance is provided on a pro forma basis, which excludes the impact of this business we expect to divest next year.
Maxwell Krakowiak · Statement from
Chronological order, not a duration scale. Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Revvity (RVTY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 26, 2026, except a card that shows its own read date.
Watch the RVTY film — every key number, told as a short cinematic story
~2 min · open the film
What is Revvity (RVTY), and what does it report?
Short answer · as of
Revvity sells research and diagnostic workflows to pharmaceutical and biotechnology companies, laboratories, academic institutions, healthcare organizations and public authorities.
Research dated 2026-09-13.
Revvity sells research and diagnostic workflows to pharmaceutical and biotechnology companies, laboratories, academic institutions, healthcare organizations and public authorities. Its offerings span analytical instruments, detection and imaging systems, reagents, assay platforms, informatics, subscriptions, contract research and specialized laboratory services, so revenue reflects product purchases, recurring consumables and software, and service activity rather than patient-test volume alone.
Reported sales are divided almost evenly between Diagnostics and Life Sciences. That balance matters because screening assays and genomic workflows respond to different purchasing decisions from drug-discovery tools, research reagents and analytical systems, even though many customers operate across the same scientific ecosystem.
What do the latest results show for Revvity (RVTY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $730M.
Research dated 2026-09-13.
The latest reported period brought sequential improvement in revenue, gross profit, operating profit and net income. Revenue also advanced from the comparable prior period, while recent reported earnings and sales exceeded market estimates; across the latest annual record, however, sales growth coincided with lower net income.
Management links its raised adjusted-margin outlook to stronger expected organic growth and an end-market recovery, with tariff refunds providing additional help. Those benefits are being partly redirected into strategic initiatives, supply-chain work and employees, so the margin outlook is not simply a cost-cutting story.
The outlook is presented on a pro forma basis that excludes the China immunodiagnostics operation slated for divestiture. Readers should therefore keep management's adjusted, reshaped-business narrative separate from the consolidated results on the income statement.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $729.69M Jul 5, 2026
- Latest quarter · R&D
- $48.97M Jul 5, 2026
- Latest quarter · SG&A
- $278.58M Jul 5, 2026
- Latest quarter · FMP standardized operating result
- $89.32M Jul 5, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jul 5, 2026 | $729.69M | $48.97M | $278.58M | $89.32M |
| Apr 5, 2026 | $711.12M | $57.89M | $253.88M | $75.89M |
| Dec 28, 2025 | $772.06M | $58.18M | $168.21M | $111.75M |
| Sep 28, 2025 | $698.95M | $50.80M | $241.91M | $81.90M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $711.00M Aug 4, 2026
- Latest report · revenue estimate
- $702.96M Aug 4, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 4, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 4, 2026 | $711.00M | $702.96M | $1.4100 | $1.2100 |
| May 5, 2026 | $711.12M | $704.07M | $1.0600 | $1.0200 |
| Feb 2, 2026 | $772.06M | $764.94M | $1.7000 | $1.5700 |
| Oct 27, 2025 | $698.95M | $699.36M | $1.1800 | $1.1400 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $730M | $52M | $0.47 (diluted) |
| Q1 FY2026 | $711M | $41M | $0.36 (diluted) |
| Q4 FY2025 | $772M | $98M | $0.87 (diluted) |
| Q3 FY2025 | $699M | $47M | $0.40 (diluted) |
What are the financial strengths and risks for Revvity (RVTY)?
Short answer
Cash and short-term investments were $1.02B at the Jul 5, 2026 balance-sheet date. Operating cash flow was $191.94M for the quarter ended Jul 5, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow has remained positive throughout the reported quarterly series and recently strengthened, while capital spending has stayed modest relative to that inflow. Cash and short-term investments also rebounded from the preceding period, and the liquidity ratios indicate coverage of near-term obligations.
Debt nevertheless substantially exceeds cash, leaving Revvity with a meaningful net debt position. That makes sustained cash generation important: weaker laboratory purchasing or pressure on research and diagnostic demand could reduce the flexibility available for reinvestment, debt service and portfolio changes.
Reported profitability remains well below management's adjusted-margin outlook, partly because those measures describe different bases. The pending China immunodiagnostics divestiture adds another comparability issue when judging whether operating improvement is translating into durable consolidated earnings.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $191.94M Jul 5, 2026
- Previous quarter · operating cash flow
- $115.06M Apr 5, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jul 5, 2026 | $191.94M | −$11.07M |
| Apr 5, 2026 | $115.06M | −$19.77M |
| Dec 28, 2025 | $183.28M | −$20.17M |
| Sep 28, 2025 | $138.58M | −$18.50M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Revvity (RVTY)?
Short answer · as of
The next earnings report is expected on Nov 3, 2026.
Research dated 2026-09-13.
The upcoming report should be tested against Revvity's recent pattern: revenue progression, gross-profit conversion, operating profit and the relationship between reported earnings and market expectations. Continued improvement across those measures would support management's claim that end-market demand is recovering; renewed weakness would make that claim harder to sustain.
Watch cash generation alongside the cash balance and debt, especially as management funds strategic, supply-chain and workforce initiatives. The report should also make clear how the China immunodiagnostics exclusion changes comparisons between pro forma guidance and consolidated results.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We expect to be able to generate adjusted operating margins of approximately 28.7% this year due to the stronger organic growth we now expect for the year, combined with the impact of the tariff refunds we've received, which is being partially offset by incremental reinvestments we are making in our strategic initiatives, supply chain and in our people, which should allow us to capitalize on the end market recovery that we believe is now underway.
Prahlad Singh ·
As a reminder, given the pending divestiture of our immunodiagnostics business in China, all of the following commentary and our updated guidance is provided on a pro forma basis, which excludes the impact of this business we expect to divest next year.
Maxwell Krakowiak ·
We expect this to now result in our 2026 pro forma total revenue being in the range of $2.83 billion to $2.86 billion.
Maxwell Krakowiak ·
We now anticipate our pro forma adjusted operating margins this year to be 28.7%, which is up 30 basis points from our prior guidance.
Maxwell Krakowiak ·
How does Revvity compare with its peers?
Short answer
Revvity's score ranks 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Revvity differs from a pure diagnostic laboratory because customers buy the tools and consumables that enable testing and research rather than chiefly paying Revvity to process patient samples. It also differs from a narrowly focused instrument maker: reagents, assays, software, subscriptions and laboratory services sit beside analytical and imaging systems.
The near-even contribution from Diagnostics and Life Sciences gives the company exposure to screening, genomics and infectious-disease workflows as well as drug discovery and broader scientific research. That mix spreads the sources of demand, but it also means a single industry label does not capture the purchasing cycles that shape revenue.
| Company | Price | Market value | Score |
|---|---|---|---|
| $676.77 Oct 26, 2026 | $18.9B | 94 5-pillar Oct 26, 2026 | |
| $271.04 Oct 26, 2026 | $40.9B | 93 5-pillar Oct 26, 2026 | |
| $50.39 Oct 23, 2026 | $10.4B | 88 5-pillar Oct 26, 2026 | |
| $154.51 Oct 23, 2026 | $11.0B | 84 5-pillar Oct 26, 2026 | |
| $1670.29 Oct 23, 2026 | $33.5B | 84 5-pillar Oct 26, 2026 | |
| $13.21 Oct 23, 2026 | $11.0B | 83 5-pillar Oct 26, 2026 | |
| $243.01 Oct 26, 2026 | $26.8B | 77 5-pillar Oct 26, 2026 | |
| $185.27 Oct 23, 2026 | $14.3B | 73 5-pillar Oct 26, 2026 | |
| $328.95 Oct 23, 2026 | $26.7B | 73 5-pillar Oct 26, 2026 | |
| Revvity (RVTY) — this page | $160.39 | $17.9B | 72 |
| $455.98 Oct 26, 2026 | $44.8B | 66 5-pillar Oct 26, 2026 | |
| $345.37 Oct 23, 2026 | $16.6B | 65 5-pillar Oct 26, 2026 | |
| $85.41 Oct 23, 2026 | $14.5B | 61 5-pillar Oct 26, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $100.00 – $165.00
- Consensus target
- $132.13
- Median target
- $130.00
Consensus record · Captured .
Measured against a quoted price of $160.39 (as of Oct 26, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 30
- Identified insiders
- 14
- Purchases
- 0
- Sales
- 4
- Other transactions
- 26
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 555 Period end Jun 30, 2026
- Previous quarter · holders
- 513 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| T. Rowe Price Investment Management, INC. | 18,261,177 |
| Jupiter Topco LLC | 8,637,614 |
| Edgepoint Investment Group INC. | 8,544,479 |
| Blackrock, INC. | 7,658,369 |
| Vanguard Capital Management LLC | 7,300,973 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Revvity (RVTY)?
Revvity Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
What does Revvity sell beyond diagnostic tests?
Revvity sells instruments, reagents, assay platforms, imaging and detection technologies, informatics, software subscriptions, contract research and specialized laboratory services. Its customers use these offerings across drug discovery, genomic workflows, screening and applied analysis.
How balanced are Revvity's Diagnostics and Life Sciences segments?
The segments contribute almost equally to annual revenue. This gives Revvity a business mix spanning diagnostic screening and genomic workflows alongside research tools, reagents and analytical systems.
Why does Revvity exclude China immunodiagnostics from its outlook?
Management expects to divest that operation and therefore presents updated guidance on a pro forma basis without it. Comparisons with consolidated reported results need to preserve that distinction.
Can Revvity fund reinvestment while carrying its debt load?
Recent operating cash flow has comfortably exceeded capital spending, providing internal funding capacity, and cash increased in the latest period. Debt remains substantially above cash, so the durability of that cash generation matters as strategic and supply-chain spending continues.
What is the RVTY stock price today?
The last price recorded on this page for Revvity, Inc. (RVTY) is $160.39, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RVTY price target?
The analyst consensus price target for Revvity, Inc. (RVTY) is $132.13 (range $100.00 to $165.00, median $130.00), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does RVTY pay a dividend?
Yes. Revvity, Inc. (RVTY) shows a trailing 12-month dividend yield of 0.18%, as of Oct 23, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (83 figures)
The 83 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Prahlad Singh (Aug 6, 2026): We expect to be able to generate adjusted operating margins of approximately 28.7% this year due to the stronger organic growth we now expect for the year, combined with the impact of the tariff refunds we've received, which is being partially offset by incremental reinvestments we are making in our strategic initiatives, supply chain and in our people, which should allow us to capitalize on the end market recovery that we believe is now underway. Maxwell Krakowiak (Aug 6, 2026): As a reminder, given the pending divestiture of our immunodiagnostics business in China, all of the following commentary and our updated guidance is provided on a pro forma basis, which excludes the impact of this business we expect to divest next year. Maxwell Krakowiak (Aug 6, 2026): We expect this to now result in our 2026 pro forma total revenue being in the range of $2.83 billion to $2.86 billion. Maxwell Krakowiak (Aug 6, 2026): We now anticipate our pro forma adjusted operating margins this year to be 28.7%, which is up 30 basis points from our prior guidance. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Waltham, MA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "77 4th Avenue, Waltham, MA, 02451, US". |
FMP — 72 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 3, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $160.39 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T21:14:29.536Z. | |
px.change | Change on the day | +1.02% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $17.9B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T20:00:02.000Z. Captured from FMP at 2026-10-26T21:14:28.492Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$1.62 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $730M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $81.22–$166.25 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 75.60 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.09M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.06 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Prahlad R. Singh | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 11,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $3.83B, net result $943.16M; FY2022 revenue $3.31B, net result $569.18M; FY2023 revenue $2.75B, net result −$118.38M; FY2024 revenue $2.76B, net result $295.83M; FY2025 revenue $2.86B, net result $241.68M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Diagnostics $1.42B · Life Sciences $1.43B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 52.1% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-07-05.revenue_k | Revenue — period end 2026-07-05 | $729.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-05.rd_k | R&D — period end 2026-07-05 | $48.97M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-05.sga_k | SG&A — period end 2026-07-05 | $278.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-05.operating_result_k | FMP standardized operating result — period end 2026-07-05 | $89.32M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-05.revenue_k | Revenue — period end 2026-04-05 | $711.12M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-05.rd_k | R&D — period end 2026-04-05 | $57.89M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-05.sga_k | SG&A — period end 2026-04-05 | $253.88M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-05.operating_result_k | FMP standardized operating result — period end 2026-04-05 | $75.89M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-28.revenue_k | Revenue — period end 2025-12-28 | $772.06M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-28.rd_k | R&D — period end 2025-12-28 | $58.18M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-28.sga_k | SG&A — period end 2025-12-28 | $168.21M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-28.operating_result_k | FMP standardized operating result — period end 2025-12-28 | $111.75M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.revenue_k | Revenue — period end 2025-09-28 | $698.95M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.rd_k | R&D — period end 2025-09-28 | $50.80M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.sga_k | SG&A — period end 2025-09-28 | $241.91M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.operating_result_k | FMP standardized operating result — period end 2025-09-28 | $81.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-04.revenue_actual | Revenue · reported — report date 2026-08-04 | $711.00M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.revenue_estimated | Revenue · estimate — report date 2026-08-04 | $702.96M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_actual | EPS · reported — report date 2026-08-04 | $1.4100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_estimated | EPS · estimate — report date 2026-08-04 | $1.2100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_actual | Revenue · reported — report date 2026-05-05 | $711.12M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_estimated | Revenue · estimate — report date 2026-05-05 | $704.07M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_actual | EPS · reported — report date 2026-05-05 | $1.0600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_estimated | EPS · estimate — report date 2026-05-05 | $1.0200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-02.revenue_actual | Revenue · reported — report date 2026-02-02 | $772.06M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-02.revenue_estimated | Revenue · estimate — report date 2026-02-02 | $764.94M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-02.eps_actual | EPS · reported — report date 2026-02-02 | $1.7000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-02.eps_estimated | EPS · estimate — report date 2026-02-02 | $1.5700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-27.revenue_actual | Revenue · reported — report date 2025-10-27 | $698.95M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-27.revenue_estimated | Revenue · estimate — report date 2025-10-27 | $699.36M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-27.eps_actual | EPS · reported — report date 2025-10-27 | $1.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-27.eps_estimated | EPS · estimate — report date 2025-10-27 | $1.1400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $1.02B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $191.94M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-07-05. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $3.34B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 2.45× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-07-05.operating_cash_flow_m | Operating cash flow — period end 2026-07-05 | $191.94M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-04-05.operating_cash_flow_m | Operating cash flow — period end 2026-04-05 | $115.06M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-07-05.capex_m | Capital expenditure (reported) — period end 2026-07-05 | −$11.07M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-04-05.capex_m | Capital expenditure (reported) — period end 2026-04-05 | −$19.77M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-28.operating_cash_flow_m | Operating cash flow — period end 2025-12-28 | $183.28M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-28.capex_m | Capital expenditure (reported) — period end 2025-12-28 | −$20.17M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-28.operating_cash_flow_m | Operating cash flow — period end 2025-09-28 | $138.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-28.capex_m | Capital expenditure (reported) — period end 2025-09-28 | −$18.50M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $100.00 – $165.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $132.13 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $130.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 30 transactions · 0 purchases, 4 sales, 26 other transactions · 14 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 555 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 513 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | T. Rowe Price Investment Management, INC. — shares in provider snapshot | 18,261,177 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Jupiter Topco LLC — shares in provider snapshot | 8,637,614 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Edgepoint Investment Group INC. — shares in provider snapshot | 8,544,479 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Blackrock, INC. — shares in provider snapshot | 7,658,369 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vanguard Capital Management LLC — shares in provider snapshot | 7,300,973 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 8 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-12 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 3.36 · Piotroski F 8 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-25 · Expired observation |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 17.50× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $1.02B at Jul 5, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-26. Balance-sheet reference date: 2026-07-05. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.28 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-26, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.18% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-04.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($711.00M) with the recorded estimate ($702.96M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-04.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($1.4100) with the recorded estimate ($1.2100) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 72 of 100 · Strong · pillars 76 / 47 / 49 / 36 / 96 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 72 (stored snapshot Oct 24, 2026) → 72 (current publication computed Oct 26, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-07-05. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-07-05.revenue_k,fin.q_table.depth.2026-07-05.rd_k,fin.q_table.depth.2026-07-05.sga_k,fin.q_table.depth.2026-07-05.operating_result_k,fin.q_table.depth.2026-04-05.revenue_k,fin.q_table.depth.2026-04-05.rd_k,fin.q_table.depth.2026-04-05.sga_k,fin.q_table.depth.2026-04-05.operating_result_k,fin.q_table.depth.2025-12-28.revenue_k,fin.q_table.depth.2025-12-28.rd_k,fin.q_table.depth.2025-12-28.sga_k,fin.q_table.depth.2025-12-28.operating_result_k,fin.q_table.depth.2025-09-28.revenue_k,fin.q_table.depth.2025-09-28.rd_k,fin.q_table.depth.2025-09-28.sga_k,fin.q_table.depth.2025-09-28.operating_result_k. - Earnings-history note. Source series as of 2026-08-04. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-04.revenue_actual,earn.history.depth.2026-08-04.revenue_estimated,earn.history.depth.2026-08-04.revenue_actual.comparison,earn.history.depth.2026-08-04.eps_actual.comparison,earn.history.depth.2026-08-04.eps_actual,earn.history.depth.2026-08-04.eps_estimated,earn.history.depth.2026-05-05.revenue_actual,earn.history.depth.2026-05-05.revenue_estimated,earn.history.depth.2026-05-05.eps_actual,earn.history.depth.2026-05-05.eps_estimated,earn.history.depth.2026-02-02.revenue_actual,earn.history.depth.2026-02-02.revenue_estimated,earn.history.depth.2026-02-02.eps_actual,earn.history.depth.2026-02-02.eps_estimated,earn.history.depth.2025-10-27.revenue_actual,earn.history.depth.2025-10-27.revenue_estimated,earn.history.depth.2025-10-27.eps_actual,earn.history.depth.2025-10-27.eps_estimated. - Cash-flow note. Source series as of 2026-07-05. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-07-05.operating_cash_flow_m,fin.opcf.depth.2026-04-05.operating_cash_flow_m,fin.opcf.depth.2026-07-05.capex_m,fin.opcf.depth.2026-04-05.capex_m,fin.opcf.depth.2025-12-28.operating_cash_flow_m,fin.opcf.depth.2025-12-28.capex_m,fin.opcf.depth.2025-09-28.operating_cash_flow_m,fin.opcf.depth.2025-09-28.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Diagnostics: $1.42B; Life Sciences: $1.43B | 2025-12-28 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-07-05 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Cash, investments and debt | Total debt: $3.34B; Liquidity basis: cash and short-term investments; Total liabilities: $4.82B; Cash and short-term investments: $1.02B; Cash and investments: $1.02B; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-07-05 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-06 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Diagnostics & Research The company's SEC filings classify it under SIC 3826 — Laboratory Analytical Instruments. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-28 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-04 | FMP | Financial Modeling Prep (FMP) earnings |
| Most recent periodic reports | 2026-08-11 | OFFICIAL | SEC EDGAR filer submissions | |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-07-05 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $1.02B; Cash and short-term investments: $1.02B; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-07-05 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-07-05 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-07-05; From: 2024-09-29; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $1.02B; Decline: $206.80M; Opening balance: $1.23B; Average change per period: $29.50M Change in cash, cash equivalents and short-term investments between the 2024-09-29 and 2026-07-05 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-07-05 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-07-05; Cash basis: cash and short-term investments; Net cash: -$2.32B; Total debt: $3.34B; Cash and investments: $1.02B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-07-05 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 1.5; Current ratio: 1.8; Debt to equity: 0.46; Net margin: 8.2%; Gross margin: 52.1%; Operating margin: 12.3%; Return on assets: 2%; Return on equity: 3.3% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 2.88; Piotroski F-score: 8 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Next earnings report | Date: 2026-10-26; EPS estimate: $1.28 per share; Revenue estimate: $694.44M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Recent SEC filings |
| 2026-08-11 | OFFICIAL | SEC EDGAR filer submissions |
Data provided for informational purposes only.